Loading...
Wir würden uns freuen, wenn du Teil unserer Community wirst. Tritt unserem Discord bei um dich mit uns und anderen Mitgliedern zu vernetzen!
- Ticker
- SKIKON.CO
- Price
- 825.90
- Stock movement down
- -9.50 (-1.09%)
- Company name
- SKAGEN Kon-Tiki A
- Exchange
- (CO ,
- Currency
- DKK )
- Marktkapitalisierung
- -
- Ent-Wert
- -
- Preis/Umsatz
- -
- Preis/Buch
- -
- Div-Ertrag
- -
- Div Wachstum
- -
- Wachstumsjahre
- -
- FCF-Ausschüttung
- -
- Nachlaufendes KGV
- -
- Forward P/E
- -
- PEG
- -
- EPS-Wachstum
- -
- 1 Jahr Rückkehr
- 19.58%
- 3-Jahres-Rendite
- -1.52%
- 5-Jahres-Rendite
- 9.62%
- 10-Jahres-Rendite
- 3.84%
Zuletzt aktualisiert: 2025-09-05
DIVIDENDS
SKIKON.CO keine Dividenden ausschüttet
BEWERTUNG
Bewertungskennzahlen
Loading...
Daten zu den Bewertungsverhältnissen
| Nachlaufendes KGV | - |
| Preis zu OCF | - |
| Preis zu FCF | - |
| Preis zu EBITDA | - |
| EV zu EBITDA | - |
Bewertung (Umsatz/Buchwert)
Loading...
Bewertungsdaten (Umsatz/Buchwert)
| Preis zu Umsatz | - |
| Preis zum Buchen | - |
| EV zu Verkäufen | - |
FINANZEN
BESTANDSINFORMATIONEN
Aktienchart
Loading...
Daten zum Aktienkurs
| Öffnen Sie | 862.50 |
| Tageshöchststand | 862.50 |
| Tägliches Tief | 862.50 |
| Tägliches Volumen | 0K |
| Allzeithoch | 1070.92 |
| 1-Jahres-Analystenschätzung | - |
| Beta | - |
| EPS (TTM) | - |
| Dividende je Aktie | - |
| Ex-Div-Datum | - |
| Nächstes Ergebnisdatum | - |
Nachteiliges Potenzial
Loading...
Nachteilige potenzielle Daten
| SKIKON.CO | S&P500 | |
| Aktueller Preisrückgang vom Allzeithoch | -19.46% | -1.06% |
| Höchster Preisrückgang | -57.82% | -56.47% |
| Datum des höchsten Rückgangs | 27 Oct 2008 | 9 Mar 2009 |
| Durchschnittlicher Rückgang vom Höchststand | -14.05% | -10.99% |
| Durchschnittliche Zeit bis zum neuen Höchststand | 26 days | 12 days |
| Maximale Zeit bis zum neuen Höchststand | 654 days | 1805 days |
UNTERNEHMENSDATEN
Marketcap
-
Kategorie Marktkapitalisierung
Small-cap
Beschreibung
SKAGEN - Kon-Tiki fund is an open-ended equity mutual fund launched and managed by Skagen AS. The fund invests in public equity markets of emerging countries across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund invests in stocks of companies across diversified market capitalizations. It invests in value stocks of companies. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. SKAGEN - Kon-Tiki fund was formed on April 5, 2002 and is domiciled in Norway.
Mitarbeiter
0
Investor Relations
-
SEC-Anmeldungen
CEO
Land
Denmark
Stadt
Art des Bestands
-
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
DAS GESCHÄFT VERSTEHEN
Loading...
UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhage...
27. Oktober 2025
Lysaker, 27 October 2025 With reference to Nasdaq Copenhagen's rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as deta...
27. Oktober 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. September 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. September 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. September 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. September 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9. September 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9. September 2025
Lysaker, 10 July 2025 The semi annual report for securities funds managed by Storebrand Asset Management AS was approved by the Board of Directors today, and has now been released (only in Norwegian l...
10. Juli 2025
Lysaker, 5 June 2025 The prospectuses have been updated as the document structure between SKAGEN funds and Storebrand funds have been aligned with the latter. There are no material changes, but all pr...
5. Juni 2025
Nächste Seite